Every 23 seconds, another American was diagnosed with diabetes. This soaring incidence has become more apparent during the Covid-19 pandemic, which scientists still don’t fully understand because of the high rates of severe illness and mortality among people with diabetes. 2021, Diabetes-related deaths soar This is a 15% drop from pre-pandemic levels.
The financial consequences are equally astounding.An estimate calculates the overall economic impact of diabetes and prediabetes $400B+ per year.
but, no coordinated strategy to deal with this growing crisis.
The current insulin pricing discussion demonstrates our piecemeal approach. People with type 1 diabetes (about 5% of the total diabetic population) need it to survive, while many people with type 2 diabetes rely on insulin to control their blood sugar. Sadly, 1 in 4 Americans Diabetes reports ration this life-saving drug because they can’t afford it.
Politicians on both sides of the aisle are rightfully eager to make more insulin affordable. The House has passed bipartisan legislation to limit out-of-pocket insulin costs to $35 a month and take other steps to ensure affordable use.Senators Shaheen and Collins just introduced a bipartisan companionwe hope Congress will reach an agreement within the next few months to bring it to the president.
That said, the system is so sick that making insulin cheaper is a bit like putting a Band-Aid on a bullet wound.Policymakers should also support diabetes reverse Treatments that help patients normalize blood sugar levels while reducing or eliminating the need for insulin.
This seems to run counter to standard metabolic disease care. Often, diabetes is viewed as a chronic progressive disease that requires increased drug levels to avoid complications.
But the status quo is changing. There are new evidence-based treatments that have been shown to reverse the progression of diabetes and prediabetes, enabling patients to achieve remission and forgo insulin and other diabetes medications.Just last year, an international Consensus report For the first time, medical and scientific experts have defined diabetes remission criteria and acknowledged diabetes reversal—the process of returning blood sugar to normal levels without medication.
So, how does the U.S. healthcare system support patients who want remission? We recommend the following steps:
- Modernize quality metrics for people with type 2 diabetes. Incentives for measuring and recognizing high-quality care for people with diabetes should be updated to encourage normalization of blood sugar levels, with appropriate withdrawal of diabetes-related medications. We recognize that not everyone is ready to seek relief, but the system should reward clinicians and payers who support these efforts.
- Use policy levers to emphasize prevention and more effective treatment. Medicare Diabetes Prevention Program Creates new opportunities to expand benefits Innovation CenterHowever, efforts should be expanded to include secondary prevention (eg, more effective treatment regimens) and other modalities, including virtual care, that provide evidence of comparable or better outcomes.
- Improve drug price transparency. The opacity of the current system makes true market-based competition nearly impossible. Increased price transparency at every step of the process between manufacturers and patients will reveal problems and help reveal potential solutions. This may require lowering barriers to entry for competing insulin makers.
- Modernize nutrition policy and advice. The one-size-fits-all nutrition model is outdated. The growing prevalence of diabetes, obesity, and fatty liver disease provides evidence that we have yet to resolve. It is time for comprehensive nutrition policy reform to address the underlying causes of metabolic disease.This includes the use of targeted evidence-based guidance and a comprehensive reassessment of subsidies and incentives – some of which may have contributed to our current metabolic crisis– Advancing food policy and access.
Crucially, improving population-level diabetes care and prevention offers a huge opportunity to address the disproportionate burden of diabetes on underserved and minority groups. With health equity taking center stage, implementing a strategic plan to fight diabetes will set concrete measures for success.
Finally, limit the price of insulin for patients Does not affect the unsustainable trajectory of the type 2 diabetes epidemic in the United States. Ironically, it could even lead to cost shifting, with total prices and premiums changing to make up for lost revenue.
Until resources are dedicated to expanding access to treatments that help reverse diabetes, we will continue to fight a losing battle. It’s time to change conversations, incentives and policy solutions to help people improve their health and get off medication — not just make them cheaper.
Photo: Maxim Luzkin, Getty Images
